TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02144454

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saturated fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fat
Study: NCT03694028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limb Loading
Description: Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
Study: NCT03420768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Administered by intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion
Study: NCT03694028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
Study: NCT02857972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wondaleaf®
Description: Use of Wondaleaf® during menstruation every night in one menstrual cycle.
Study: NCT00707564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing
Description: The HemCon Dental Dressing is an oral wound dressing made of chitosan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze with pressure
Description: Gauze with pressure
Study: NCT02694978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCM
Study: NCT02737592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Simply Pleasure Personal Lubricant
Description: silicone base without sensate
Study: NCT00682617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
Study: NCT01752049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical timolol maleate
Description: * Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline drops
Description: Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
Study: NCT02769793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa dispersible
Description: Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Study: NCT02229617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous testosterone
Study: NCT00678704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 10 mg tablet prior to intercourse on demand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 20 mg tablet prior to intercourse on demand

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet prior to intercourse on demand
Study: NCT03377751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional posterior wall isolation
Description: PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voltage-guided substrate homogenization
Description: PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI only group
Description: PVI will be performed in this arm.
Study: NCT00025415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02150161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/ ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT02646410

Intervention type: OTHER
Group type: OTHER
Intervention: FPD+NDOT

Intervention type: OTHER
Group type: OTHER
Intervention: FPD+DOT

Intervention type: OTHER
Group type: OTHER
Intervention: DDD+NDOT
Description: Door to door delivery + non directly observed treatment

Intervention type: OTHER
Group type: OTHER
Intervention: DDD+DOT
Description: Door to door delivery + directly observed treatment
Study: NCT02018211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: passive recovery following exercise test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: graduated compression socks
Description: graduated compression socks worn after test exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation device
Description: neuromuscular electrical stimulation device worn after test exercise
Study: NCT02998190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Doses of EB8018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Doses of EB8018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple Ascending Doses of placebo
Study: NCT00030264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
Study: NCT01280942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWS Nursing Alerts
Description: An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Remote Sensor
Description: A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
Study: NCT03379974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP Inhalant Product
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP Inhalant Product
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP Inhalant Product
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
Study: NCT02218502

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound by general gynaecologist
Description: All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound by general gynaecologist
Description: All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound by an expert ultrasonographist
Description: Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.

Intervention type: OTHER
Group type: OTHER
Intervention: DW-MRI
Description: Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Give blood sample
Description: Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
Study: NCT03945942

Intervention type: DEVICE
Group type: OTHER
Intervention: Near infrared spectroscopy with INVOS device
Description: somatic and cerebral oximetry by INVOS in pediatric liver transplantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Near infrared spectroscopy with Foresight device
Description: somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
Study: NCT03347942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will also serve the dish of the form, but can serve additional portion without waiting.
Study: NCT02921399

Intervention type: OTHER
Intervention: eradication timing
Description: patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.

Intervention type: OTHER
Intervention: eradication timing
Description: patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
Study: NCT00579189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study: NCT03101436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil and Red Wine
Description: Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil and Red Wine
Description: Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)
Study: NCT04476095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT
Description: Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study: NCT04589000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table.
Study: NCT04570631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous (IV) or Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous (IV) or Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet
Study: NCT03336450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP615
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHOS/SHP615
Description: MHOS/SHP615
Study: NCT02401633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO-CPR
Description: CPR provided by bystander with chest-compressions only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S-CPR
Description: CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
Study: NCT00910754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablets administered orally twice daily.
Study: NCT04536441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra Brief Online Mindfulness-based Intervention
Description: We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
Study: NCT06281704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 IV
Description: AK101 will be administered intravenously.
Study: NCT03379974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
Study: NCT06281704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 SC
Description: AK101 will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 SC
Description: AK101 will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 SC
Description: AK101 will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously or intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 IV/AK101 SC
Description: AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 IV/AK101 SC
Description: AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
Study: NCT02239796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTrac continence stimulators
Description: Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroTrac continence stimulators
Description: We are using NeuroTrac continence stimulators.
Study: NCT03600935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vancouver Clinical Pathway
Description: Vancouver Clinical Pathway
Study: NCT02798718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: full-fat milk
Description: intake 250ml full-fat milk per day, do not intake any other dairy products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: full-fat milk
Description: intake 250ml full-fat milk per day, do not intake any other dairy products
Study: NCT04574635

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT01397552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg/mL injected into lumbar spine, one level, one injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: 80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time